drug · small molecule
admilparant
Phase 3updated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
indications
indications
Pulmonary Fibrosis
all catalysts(0)
nothing on the calendar yet
Trials studying admilparant
News(10)
- BMS R&D head to depart amid restructureBristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.biospace · 4d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 18d ago
- Syndax ends fibrosis program for Niktimvo after mid-stage disappointmentSyndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was appro…biospace · 1mo ago
- Bristol Myers dips on ‘confounding’ lung drug resultsOnly the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.biopharma_dive · 1mo ago
- BMS’ Phase 3 win for lung drug clouded by high-dose missA low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…biospace · 1mo ago
- Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugsBristol Myers Squibb reported two Phase 3 successes on Monday morning, including for an experimental drug that recently ran into safety issues. A trial testing the lung disease program admilparant…endpoints · 1mo ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 1mo ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 1mo ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 1mo ago
- Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshakenThe revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to di…fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that